Serum fatty acid binding protein 4 is positively associated with early stroke recurrence in nondiabetic ischemic stroke

Bo Li1,2,3,4, Jun Wu1,2,3,4, Pengjun Jiang1,2,3,4, Maogui Li1,2,3,4, Qingyuan Liu1,2,3,4, Yong Cao1,2,3,4, Shuo Wang1,2,3,4

1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2China National Clinical Research Center for Neurological Diseases, Beijing, China
3Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
4Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing, China

Correspondence to: Shuo Wang; email: captian9858@126.com
Keywords: adipocyte fatty acid–binding protein, stroke recurrence, ischemic stroke
Received: January 3, 2019 Accepted: March 20, 2019 Published: April 9, 2019

ABSTRACT

Adipocyte fatty acid–binding protein (FABP4) played critical roles in metabolic syndrome, inflammatory responses and cardiovascular diseases. It aimed to investigate the associations of serum FABP4 levels with early stroke recurrence. This study included the 206 acute ischemic stroke patients hospitalized in our institution. Stroke recurrence events were assessed at the 3-month follow-up. The median of FABP level was 22.6 (IQR, 17.9-31.6) ng/mL in patients with stroke recurrence (N=36), which was higher than in patients without stroke recurrence [16.9 (IQR, 11.8-21.4) ng/mL] (P<0.001). As a continuous variable, the unadjusted and adjusted risk of stroke recurrence would be increased by 12% (OR=1.12 [95% CI 1.06–1.17], P<0.001) and 8% (1.08 [1.02–1.14], P=0.006) for every 1 ng/ml increment of FABP4. The Area under the curve (AUC) of serum FABP4 and NIH Stroke Scale (NIHSS) score for predicting stroke recurrence was 0.73 (95% CI: 0.64–0.82) and 0.72 (95% CI: 0.64–0.81), presenting no discriminating capacity (P=0.45). In the combining model, the AUC of NIHSS score was further improved to 0.77 by FABP4 (0.77; 95% CI: 0.69–0.85), which was significant (P=0.01). The risk of stroke recurrence can be predicted by elevated FABP4 levels in serum of nondiabetic patients with first-ever ischemic stroke.

INTRODUCTION

Stroke has been the cause of approximately 5 % of all disability-adjusted life-years, as well as 10 % of all mortality globally [1]. In China, stroke lead to nearly 1.6 million deaths each year, and there are also 7.5 million people survived from stroke [2]. Furthermore, 15%-30% of those survivors would be suffered from life-long disability [2]. There was study reported that in 2016, global lifetime risk of stroke could be 25 % since the age of 25 years. Thereinto, the estimated risk was highest for China, which was 39.3% (95% uncertainty interval, 37.5 to 41.1) [3].

Adipocyte fatty acid–binding protein (FABP4/aP2) has been reported to function in metabolite and inflammation [4]. Previous studies performed on FABP4-deficient mice indicated that this lipid cha-perone made important effects on metabolic syndrome [5], insulin resistance [6] and atherogenesis [7]. Another study suggested that aP2-targeted small-molecule inhibitors may be a new therapy for the prevention and treatment of metabolic diseases (e.g. type 2 diabetes or atherosclerosis) [8]. Furthermore, clinical research also suggested that FABP4 played critical roles in macrophage cholesterol trafficking and inflammation, and may promote the obesity development [9], insulin
resistance [10], metabolic syndrome [11], diabetes [12], gestational diabetes mellitus [13], hypertension [14] and atherosclerosis [5, 15-17].

Interestingly, one study reported that serum FABP4 levels in elderly population were related to an elevated risk of developing central arterial stiffness [18]. A community-based cohort study reported that the cardiovascular diseases could be predicted with the circulating FABP4 level [19]. Furthermore, a case-control study [20] indicated that ischemic stroke was significantly correlated with serum FABP4, which might be applied as prognostic indicator for early mortality. In addition, FABP4 was also related to various poor outcomes in patients with acute ischemic stroke [21]. Above results indicated the potential role of FABP4 in stroke. Thus, we hypothesized that FABP4 level in serum was related to the prevalence of stroke recurrence in nondiabetic ischemic stroke. The serum FABP4 levels were in 206 Han Chinese nondiabetic patients with ischemic stroke, and the associations between serum FABP4 levels and stroke recurrence in 3-month follow-up were explored.

RESULTS

Descriptive characteristics of stroke patients

324 patients with ischemic stroke were included. 255 patients were recorded after excluding 45 with diabetes mellitus, 8 with tumors, 6 inflammatory disease and 10 with abnormal renal and liver function. There were 9 lost to follow-up and 5 withdrew. Finally, 241 patients completed follow-up and 206 patients were included (35 patients died during follow-up). The FABP levels of those patients were collected and analyzed. The median value of FABP levels was calculated as 17.7 (IQR, 12.7–22.8) ng/ml and the median value of age was 59 (IQR, 48-73) years. The median NIHSS score was 7 (IQR, 4-12) points during their hospitalization. The baseline information of all patients was summarized (Table 1).

Main results

A positive relationship was observed between serum FABP4 levels and stroke severity, since the stroke severity was evaluated with NIHSS score (r=0.493, P<0.001), Table 2. Furthermore, results indicated that FABP4 was correlated with lesion size, suggesting a positive relationship between FABP4 and the infarct volume (r=0.183, P=0.003). A modest correlation was also observed between FABP4 and Hs-CRP (r=0.141, P=0.043). However, no significant correlation was observed between FABP4 and gender, age and HCY (P>0.05 for all), Table 2. The correlation of FABP4 levels with stroke subtypes was also tested. The median FABP4 levels were higher for cardioembolic stroke [n=77] compared to those of other stroke subtypes [N=129] (18.9 [IQR, 14.0-27.8] vs. 17.3 [11.2-21.7] ng/ml; P=0.012; Figure 1A), with significance. In addition, FABP4 levels in obese patient (N=31) was higher than in non-obese (N=175) patients (21.9[IQR, 17.0-25.8] vs. 17.1[12.1-21.6]ng/ml; P<0.001), Figure 1B.

Figure 1. Distribution of serum levels of FABP4 in different subgroups. (A) Serum levels of FABP4 in cardioembolic stroke and other stroke subtype groups. (B) Serum levels of FABP4 in obese and non-obese group. All data are medians and inter-quartile ranges (IQR). P values refer to Mann-Whitney U tests for differences between groups. FABP4= Fatty Acid Binding Protein 4.
Stroke recurrence was observed in 36 patients (17.5%; 95%CI: 12.3%-22.7%). Median of serum FABP4 levels in patients with stroke recurrence was 22.6 (IQR, 17.9-31.6) ng/mL, which was higher than those of without stroke recurrence [16.9, (IQR, 11.8-21.4) ng/mL] (Figure 2). The difference was significant (P<0.001).

The OR of serum FABP4 levels compared to NIHSS and other risk factors was calculated in logistic regression analysis. For each 1 ng/ml increment of FABP4 level in serum, the risk of stroke recurrence would be elevated by 12% in unadjusted model (with the OR of 1.12 [95% CI 1.06–1.17], P<0.001) and 8% in adjusted model (1.08 [1.02–1.14], P=0.006) (Table 2). In addition, NIHSS, stroke etiology, atrial fibrillation, HCY and Hs-CRP were also significant indicators (P<0.05 for all) (Table 3).

The distribution of stroke recurrence across the FABP4 quartiles was ranged from 5.8% (Q1) to 34.0% (Q4) (Figure 3). For stroke recurrence, the OR of FABP4 Q4 against Q1 was 4.55 (95% CI, 2.03–12.15; P=0.001), while for Q2 and Q3, the OR was 1.77 (95% CI, 0.85–7.94; P=0.51) and 2.49 (95% CI, 0.95-10.12 P=0.12), respectively (Table 4). Furthermore, elevated serum

### Table 1. Baseline characteristics of 206 patients with stroke.

|                          | N=206  |
|--------------------------|--------|
| Age (years), medians (IQRs) | 59(48-73) |
| Sex-male, n (%)           | 112(54.4) |
| BMI (kg/m2), medians (IQRs) | 26.7(24.8-28.2) |
| Time from onset to blood collection(hours), medians (IQRs) | 22.5(13.0-28.5) |
| Vascular risk factors, n (%) |       |
| Hypertension              | 141(68.4) |
| Hypercholesterolemia      | 55(26.7) |
| Atrial fibrillation       | 46(22.3) |
| Coronary heart disease    | 22(11.7) |
| Previous TIA              | 25(12.1) |
| PVD                       | 11(5.3) |
| Acute treatment, no. (%)  |        |
| TPA-T                     | 52(25.2) |
| Mechanical thrombectomy   | 9(4.4)  |
| Mechanical thrombectomy and/or TPA-T | 57(27.7) |
| NIHSS at admission, medians (IQR) | 7(4-12) |
| Lesion volumes (ml), median (IQR) | 21.8(8.6-35.9) |
| Stroke etiology no. (%)   |        |
| Small-vessel occlusive    | 42(20.4) |
| Large-vessel occlusive    | 40(19.4) |
| Cardioembolic             | 77(37.4) |
| Other                     | 20(9.7)  |
| Unknown                   | 27(13.1) |
| Laboratory findings, medians (IQR) |       |
| Hs-CRP, mg/dl             | 0.74(0.27-1.87) |
| HCY, umol/l               | 16.6(12.4-20.5) |
| FABP4, ng/ml              | 17.7(12.7-22.8) |

IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; TPA-T: Tissue plasminogen activator-treated; Hs-CRP, high C-reactive protein; HCY, homocysteine; TIA, Transient ischemic attack; PVD, peripheral vascular disease; FABP4; Fatty Acid Binding Protein 4.
levels of FABP4 (>22.8 ng/ml) were correlated with stroke recurrence, in which the risk was elevated by 272 % (OR=3.72 [95% CI 1.74–7.92], P<0.001) and 129 % (2.29 [1.31–5.11], P=0.003), respectively.

The discriminating capacity of FABP4 for predicting stroke recurrence was evaluated with AUC (0.73, 95% CI 0.64–0.82). The result was compared with Hs-CRP (AUC 0.69; 95% CI 0.61–0.77; P=0.02), HCY (AUC 0.70; 95% CI 0.61–0.80; P=0.03) and NIHSS score (AUC 0.72; 95% CI 0.64–0.81; P=0.45) (Table 5 and Figure 4). Interestingly, in a model combining NIHSS score and FABP4, the AUC was increased and reached 0.77 (95% CI, 0.69–0.85), indicating that NIHSS score could be significantly improved with FABP4 (P=0.01). The FABP4-improved discriminating capacity was further confirmed with the internal 5-fold cross validation. The AUC (mean ± SD) was 0.73± 0.046 and 0.77± 0.040 for the NIHSS and the combining model, respectively, amount to a difference of 0.04± 0.006). The 5-fold cross-validated mean squared prediction error was 0.209 ± 0.014 and 0.196 ± 0.014 for the NIHSS and the combining model, respectively, amount to an average decrease of 0.013 ± 0.004). Further, higher discriminating capacity was observed in a model combining known risk factors and FABP4, compared to the model only involving known risk factors without FABP4 (P=0.009).

Table 2. The correlation between FABP4 and other factors.

| Factors       | r[spearman] | p          |
|---------------|-------------|------------|
| NIHSS         | 0.493       | <0.001     |
| Infarct volume| 0.183       | 0.003      |
| Hs-CRP        | 0.141       | 0.043      |
| BMI           | 0.228       | <0.001     |
| Sex           | 0.086       | 0.366      |
| age           | 0.127       | 0.092      |
| HCY           | 0.093       | 0.269      |

Hs-CRP, High-sensitivity- C-reactive protein; NIHSS, National Institutes of Health Stroke Scale; HCY, homocysteine; FABP4, Fatty Acid Binding Protein 4.

Figure 2. Distribution of serum levels of FABP4 in ischemic stroke patients with stroke recurrence and without stroke recurrence. All data are medians and inter-quartile ranges (IQR). P values refer to Mann-Whitney U tests for differences between groups. FABP4= Fatty Acid Binding Protein 4.
Subgroup analysis

In the analysis, those patients with endpoint of all-cause death (N=35) were taken into account. A significantly higher discriminating capacity was still observed for FABP4 to predict stroke recurrence (AUC, 0.75; 95% CI, 0.70–0.81), compared to Hs-CRP (AUC 0.70; 95% CI, 0.62–0.76; P=0.009), HCY (AUC 0.71; 95% CI, 0.63–0.78; P=0.01) and NIHSS score (AUC 0.77; 95% CI, 0.70–0.83; P=0.09).

In addition, we also conducted analyses separately among patients who defined as obese (BMI≥30kg/m²) and non-obese. In the multivariate analysis, the date showed that for each 1 ng/ml increase of FABP4, the association between FABP4 and stroke recurrence was
stronger among patients who defined as obese (OR=1.14, 95%CI: 1.09-1.22; P<0.001) versus non-obese (OR=1.06, 95%CI: 1.02-1.14; P=0.016).

**DISCUSSION**

FABP4, a third adipokine, functions as a critical mediator for inflammation in macrophages [22]. Peeters et al. [23] demonstrated the correlation between FABP4 levels and unstable plaque phenotype in atherosclerotic lesions, as well as the elevated risk of cardiovascular diseases in the follow-up. Our study has been the first study showed that nondiabetic stroke patients with elevated levels of FABP4 were more likely suffered from stroke recurrence in the future. The dose-dependent correlation was independent of existing stroke risk factors.

| Table 4. Logistic regression model for serum levels of FABP4 quartiles using stroke recurrence as the dependent variables. |
|---------------------------------|----------------|-----------------------------|----------------|-------------------|
| FABP4                          | SR/All, %      | OR (95%CI)                  | P              | OR (95%CI)        | P              |
| Q1(<12.7ng/ml)                  | 3/52, 5.8      | Reference                   | —              | Reference         | —              |
| Q2(12.7-17.7ng/ml)              | 6/52, 11.6     | 2.13(0.50-9.02)             | 0.30           | 1.77(0.85-7.94)   | 0.51           |
| Q3(17.8-22.8ng/ml)              | 10/52, 19.2    | 3.89(1.00-15.07)            | 0.038          | 2.49(0.95-10.12)  | 0.12           |
| Q4(>22.8ng/ml)                  | 17/50, 34.0    | 8.41(2.28-31.01)            | <0.001         | 4.55(2.03-12.15)  | 0.001          |
| Elevated vs. normal†            | 17/50 vs. 36/170| 3.72(1.74-7.92)           | <0.001         | 2.29(1.31-5.11)   | 0.003          |

†Adjustment by age, sex, BMI, time from onset to blood collection, infarct volume, NIHSS score, stroke etiology, vascular risk factors, acute treatment, and serum levels of Hs-CRP and HCY.
† E Elevated serum level of FABP4 was defined as >22.8ng/ml (3rd quartile).

OR, odds ratio; CI, confidence interval; BMI, body mass index; NIHSS, National Institutes of Health Stroke Scale; Hs-CRP, high C-reactive protein; HCY, homocysteine; FABP4; Fatty Acid Binding Protein 4.

SR, stroke recurrence.

**Figure 4. Receiver operator characteristic curve demonstrating sensitivity as a function of 1 specificity for predicting the stroke recurrence.** Based on the logistic model incorporating 2 biomarkers (FABP4/NIHSS) and the relative contribution of each biomarker alone (FABP4/NIHSS/Hs-CRP/HCY). NIHSS=National Institutes of Health Stroke Scale; Hs-CRP=High C-reactive protein; HCY=Homocysteine; FABP4=Fatty Acid Binding Protein 4.
The associations between FABP4 and stroke had been proposed in recent studies. Tu et al., [24] showed that FABP4 could improve existing risk stratification for patients with stroke as an independent predictor. While another study performed in type 2 diabetes patients with acute ischemic stroke confirmed that increased level of FABP4 was related to an elevated risk of poor outcomes [25]. High FABP4 levels had been related to risk and severity in patient with stroke [26]. Furthermore, serum FABP 4 concentrations were closely correlated with peripheral arterial disease in Chinese women with T2DM [27], while another study reported the association between serum FABP 4 concentration and prognosis of patients with stable angina undergoing percutaneous coronary intervention [28]. For the hypertensive patients, elevated FABP4 concentration was seen as a predictor for MetS and arterial stiffness [29]. These results revealed that FABP4 played multiple roles in stroke, which may be a promising target for treating these diseases.

The stroke recurrence was generally occurred within days and weeks after an ischemic stroke [30]. Previous community-based studies had suggested that the 3-year cumulative risk of stroke recurrence varied from 6 to 25% [31]. A previous study in Chinese stroke patients reported a recurrence rate of 10.6% in the 3-month follow-up [30]. Our study reported that 17.5% of stroke patients suffered from recurrent stroke, which was higher than in previous two studies (4.2% (95% CI, 3.2%-5.2%) [32] and 4.2% (2.8–6.2%) [33], respectively). Those differences might be resulted from study conditions, ethnicities, follow-up, diagnostic approach and disease types. The conditions of stroke recurrence are significant epidemiological data for evaluating our primary prevention, hospital care quality and secondary prevention [34].

Interestingly, a variety of studies have demonstrated that serum FABP4 levels are positively correlated with BMI [35-36]. Similarly, in this study, we also showed that FABP4 levels are positively correlated with BMI, and obese patients had significantly (P < 0.001) higher FABP4 concentrations compared with nonobese patients. However, in the multivariate analysis, serum FABP4 still was a positive risk factor for stroke recurrence independent from BMI in non-diabetic patients. Insulin resistance is linked to increased lipolysis [37], and secretion of FABP4 into the serum is stimulated by lipolysis [38]. Thus, stroke recurrence would be correlated with serum free fatty acid (FFA) levels. Interestingly, Choi et al. [39] confirmed this hypothesis, and suggested that an elevated FFA concentration could be a useful indicator for predicting recurrent stroke in cardioembolic stroke patients. Therefore, the association between FFA and stroke recurrence in non-diabetic stroke patients need to be further explored.

The mechanism of the positive association between FABP4 level and stroke recurrence risk was uncertain. Frist, recent study indicated that FABP4 was related to the increased cardiometabolic risk. Previous studies investigated the correlation between FABP4 and atherosclerosis, as well as coronary artery disease. FABP4 was directly associated with cardiac diseases, including left ventricular hypertrophy, systolic and diastolic cardiac dysfunction [40]. Increased FABP4 levels in serum was also significant correlated with a greater coronary plaque burden [41]. Second, FABP4 lead to increased blood pressure in patient with hypertension, as well as atherogenic metabolic phenotype [42], another study found that increased second trimester plasma FABP4 independently predicted gestational hypertension or preeclampsia in gestational diabetes mellitus patients [43]. Third, FABP4 was derived from fat cells, making effects on regulating the transport of non-esterified fatty acid and peroxisome

| Predictors          | Stroke recurrence   |   |
|---------------------|---------------------|---|
|                     | ROC area            | P  |
| FABP4               | 0.73(0.64-0.82)     |   |
| Hs-CRP              | 0.69(0.61-0.77)     | 0.02|
| HCY                 | 0.70(0.61-0.80)     | 0.03|
| NHISS Score         | 0.72(0.64-0.81)     | 0.45|
| Model 1 (FABP4+NIHSS) | 0.77(0.69-0.85) | 0.01|

NIIHSS, National Institutes of Health Stroke Scale; Hs-CRP, high C-reactive protein; HCY, homocysteine; FABP4; Fatty Acid Binding Protein 4; ROC, Receiver operating characteristic.
proliferator-activated receptor γ agonists. Meanwhile, both the lipid metabolism and insulin sensitivity would be influenced by interaction of FABP4 and proteins [22]. Fourth, FABP 4 may affect the endothelial cells proliferation and further angiogenesis. The aP2 played a critical role in the regulation of lipid-induced macrophage endoplasmic reticulum (ER) stress. The production of FABP4 in macrophage can be prevented with a chemical chaperone for reducing ER stress [44]. Lastly, FABP4 induced proinflammatory and proatherogenic cytokines in macrophages. One study reported that LPS-induced inflammatory responses could be enhanced with FABP4, by forming a finely-tuned positive loop between c-Jun NH2-terminal kinases and activator protein-1 [45]. FABP4 was reported to make important effects on the inflammation in metabolic alterations [46]. In addition, FABP4 was known to function in inflammation by virtue of its ability to regulate intracellular events such as lipid fluxes and signaling [47]. After suppressing FABP4 signaling, a protective effect was observed in mouse model with an acute lung injury (ALI). The lipopolysaccharide induced FABP4 expression in A549 cell would lead to increased level of reactive oxygen species, thus causing inflammatory cytokine production [48]. Interestingly, some inflammation biomarkers, such as macrophage Migration Inhibitory Factor [49] and lipoprotein (a) [50] had been suggested to be involved in stroke recurrence.

Previous studies had showed that circulating levels of FABP4 were associated with stroke risk, severity [26] and functional outcome [24] in patients with acute ischemic stroke. The prognostic value of FABP4 in in patients with type 2 diabetes and acute ischemic stroke also had been suggested [25]. However, associations between serum FABP4 levels and stroke recurrence had not been explored. In addition, in this study, patients with diabetes had been excluded. We could assess the real relationship between the FABP4 and stroke recurrence to exclude the effects caused by metabolic abnormalities. In addition, a variety of statistical methods had been used to assess the prognostic value of FABP4.

Furthermore, some limitations should be presented. First, the project design of small sample (N=206) and single center cannot produce effective results. In addition, there were only 36 recurrent strokes, leading to a relatively limited power. Thus, the adjustment in logistic regression may be too extensive with over-fitting. Second, circulating FABP4 levels were determined with a single measurement at baseline. Without serial testing of FABP4 levels, we yielded no data regarding the change of FABP4 levels in those non-diabetic stroke patients. Interestingly, one study reported significantly elevated FABP4 levels during the early hours after the occurrence of acute myocardial infarction [51]. In addition, cerebrospinal fluid samples were not obtained. Third, there were no data for other adipokine, such as leptin, omentin and retinol binding protein 4 (RBP4). The association between FABP4 and those factors should be clarified. Hence, the true association between FABP4 and stroke recurrence might be caused by those adipokines confounds. Fourth, some diabetes markers, such as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Hemoglobin A1c (HbA1c) might affect the predictive effectiveness of FABP4 in the non-diabetic patients. However, in this study, we did not test those factors due to the diabetic patients had been excluded. Thus, the impact of those factors on stroke recurrence in relation to the serum FABP4 remains unclear. Interestingly, Tu et al. [24] reported that serum FABP4 was a positive risk factor for stroke outcome independent from HOMA-IR and HbA1c. Lastly, any causal relationship could not be suggested due to the cross-sectional study design. What’s more, the patients with the secondary endpoint of all-cause death were not included in the analysis, who may also experience stroke recurrence. Therefore, the results can be under-estimated. The association between FABP4 and mortality was not evaluated, since the mortality data was not collected in current study.

In summary, this cohort study was performed on nondiabetic patients with ischemic stroke. The results indicated that increased FABP4 level in serum was related to higher risk of early stroke recurrence in the future, independent of baseline variables. Because it makes critical effects at multiple stages of stroke development, FABP4 will be worthy of further research as a possible therapeutic target.

**PATIENTS AND METHODS**

**Patients and examination**

During December 2016 and May 2018, this study included the consecutive patients hospitalized in Beijing Tian Tan Hospital, Capital Medical University (China) due to the acute ischemic stroke. Acute ischemic stroke was determined per the recommendations of World Health Organization recommendations (cerebrovascular diseases caused neurological deficit, which lasted for more than 24 hours or died within 24 hours) [52]. The diagnose was confirmed with MRI within 24 hours after the hospitalization. The exclusion criteria were as follows: (1) malignancy; (2) diabetes mellitus (the medical record reported glucose level > 7.8 mM or patient under the treatment of insulin or oral hypoglycemic agents) and/or metabolic syndrome; (3) symptoms onset more than 24h at admission; (4) liver
and kidney function dysfunction; (5) chronic co-existent inflammatory disease or other neurologic diseases.

**Clinical variables**

The information was collected, including age, gender, body mass index (BMI; obese was defined as BMI≥30kg/m²), vascular risk factors (Table 1 for details). Acute treatment was also and recorded, such as Intravenous [IV] thrombolysis and/or mechanical thrombectomy. The score of National Institute of Health Stroke Scale (NIHSS) [53] was evaluated and conducted by a certified stroke neurologist (Li HM). The stroke etiology was identified with Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria according to previous study [54]. MRI was performed for partial patients. The infarct volume was obtained according to the MRI image, with the formula of \(0.5 \times a \times b \times c\), where \(a\) was the maximal longitudinal diameter, \(b\) was the maximal transverse diameter perpendicular to \(a\), and \(c\) was the number of 10-mm slices containing infarct [55].

**Follow-up and stroke recurrence**

For all the patients, the follow-up was performed with a standard questionnaire, telephone or visit (Jiang P). Median follow-up was 3 months. Stroke recurrence was the primary endpoint, defined as suddenly deteriorated neurological function evaluated as a decreased NIHSS score of 4 or more, or a new focal neurological deficit of vascular origin lasted for >24 hours [56]. All-cause death was the secondary endpoint, defined as death due to any causes. The patients end up with the all-cause death in the follow-up were excluded [30].

**Laboratory testing**

Fasting blood of patients were drawn at 8:00 on the first hospitalization day for testing levels of FABP4. The serum FABP4 was detected with a commercial ELISA kit (R&D Systems, Minneapolis, MN). For this assay, the determination range was 1.5-100 ng/ml. The coefficient of variation intra- and inter-assay was less than 10.0% in the range of 100-10 ng/ml. In addition, other serum biomarkers were also detected, such as C-reactive protein (Hs-CRP) and homocysteine (HCY).

**Statistical analyses**

The results were expressed as percentages for categorical variables and as medians (interquartile ranges [IQRs]) for continuous variables. The comparison was conducted with Mann-Whitney U test for continuous variables and with chi-square test for categorical variables. Bivariate correlation was assessed by the Spearman's rank correlation.

The association between FABP4 and stroke recurrence was analyzed with logistic regression models. The odds ratios (ORs, 95% confidence intervals [CI]) were analyzed with both unadjusted and adjusted model. In addition, the association between stroke recurrence and FABP4 quartiles was explored, with the 1st quartile as reference. The multivariate analysis model was applied for further estimating the adjusted OR (95%CI). Further, the relationship between high FABP4 (defined as >3rd quartile=22.8ng/ml) and stroke recurrence was also presented.

Second, the risk of stroke recurrence obtained with various models were compared. The receiver operating characteristic curve (ROC) was plotted and the area under the curve (AUC) was calculated for obtaining criteria and cut-point. To test if the efficiency could be improved with FABP4 level, two nested logistic regression models were applied. In addition, optimistic bias of in-sample prediction error estimates was carefully adjusted with a fivefold cross-validation scheme [57].

The statistics were analyzed with SPSS, version 22.0. The ROC was plotted with ROCR package, version 1.0-2 (CRAN repository, http://cran.r-project.org/). P<0.05 was considered to be significant.

**Ethics**

This study has been reviewed and approved by the ethics committee of the Beijing Tian Tan Hospital, Capital Medical University. The study protocol was introduced and interpreted to all the patients and informed consents of all the involved patients were obtained.

**Ethics, consent and permissions**

Written informed consents were obtained from all patients; and, this study conformed to the principles of the Declaration of Helsinki was approved by the investigational review board of the Beijing Tian Tan Hospital, Capital Medical University.

**Data availability**

Please contact author for data requests.

**ACKNOWLEDGEMENTS**

We are grateful to the staff in the Emergency Department of our Hospital for their support with
patient recruitment. We also grateful to the patients who were included this study.

CONFLICTS OF INTEREST

On behalf of all authors, the corresponding author states that there is no conflict of interest.

FUNDING

This study was supported by the projects of National Natural Science Foundation of China (Grant No.81671129) and the National Key Research and Development Program of China (Grant No. 2016YFC1301800).

REFERENCES

1. Naghavi M, Abajobir AA, Abafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A, Ahmadi A, Ahmed MB, Aichour AN, et al, and GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390:1151–210. https://doi.org/10.1016/S0140-6736(17)32152-9

2. Tu WJ, Ma GZ, Ni Y, Hu XS, Luo DZ, Zeng XW, Liu Q, Xu T, Yu L, Wu B. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology. 2017; 88:1899–905. https://doi.org/10.1212/WNL.0000000000003937

3. The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N Engl J Med. 2018; 379:2429–37. https://doi.org/10.1056/NEJMoa1804492

4. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn KB, Parker RA, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005; 1:107–19. https://doi.org/10.1016/j.cmet.2004.12.008

5. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002; 22:1686–91. https://doi.org/10.1161/01.ATV.0000033090.81345.E6

6. Kralisch S, Klöting N, Ebert T, Kern M, Hoffmann A, Krause K, Jessnitzer B, Lossner U, Sommerer I, Stumvoll M, Fasshauer M. Circulating adipocyte fatty acid-binding protein induces insulin resistance in mice in vivo. Obesity (Silver Spring). 2015; 23:1007–13. https://doi.org/10.1002/oby.21057

7. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001; 7:699–705. https://doi.org/10.1038/89076

8. Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007; 447:959–65. https://doi.org/10.1038/nature05844

9. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006; 52:405–13. https://doi.org/10.1373/clinchem.2005.062463

10. Nakamura R, Okura T, Fujioka Y, Sumi K, Matsuzawa K, Izawa S, Ueta E, Kato M, Taniguchi SI, Yamamoto K. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, a clinical study. PLoS One. 2017; 12:e0179737. https://doi.org/10.1371/journal.pone.0179737

11. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007; 115:1537–43. https://doi.org/10.1161/CIRCULATIONAHA.106.647503

12. Liu H, Guo M, Jiang FL. Serum concentrations of fatty acid-binding protein 4 in Chinese children with type 1 diabetes mellitus. J Diabetes Complications. 2018; 32:488–91. https://doi.org/10.1016/j.jdiacomp.2017.12.009

13. Tu WJ, Guo M, Shi XD, Cai Y, Liu Q, Fu CW. First-trimester serum fatty acid-binding protein 4 and subsequent gestational diabetes mellitus. Obstet Gynecol. 2017; 130:1011–16. https://doi.org/10.1097/AOG.0000000000002310

14. Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One. 2013; 8:e81318. https://doi.org/10.1371/journal.pone.0081318
15. Xiao Y, Xiao X, Xu A, Chen X, Tang W, Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. J Diabetes Complications. 2018; 32:1100–04. https://doi.org/10.1016/j.jdiacomp.2018.09.001

16. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27:1796–802. https://doi.org/10.1161/ATVBAHA.107.146274

17. Furuhashi M, Yuda S, Muranaka A, Kawamura M, Matsumoto M, Tanaka M, Moniwa N, Ohnish H, Saito S, Shimamoto K, Miura T. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J. 2018; 82:1121–29. https://doi.org/10.1253/circj.CJ-17-1295

18. Tsai JP, Wang JH, Lee CJ, Chen YC, Hsu BG. Positive correlation of serum adipocyte fatty acid binding protein levels with carotid-femoral pulse wave velocity in geriatric population. BMC Geriatr. 2015; 15:88. https://doi.org/10.1186/s12877-015-0089-x

19. Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, Lo SV, Tse HF, Woo YC, Yeung CY, Cheung BM, Lam KS. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc. 2013; 2:e004176. https://doi.org/10.1161/JAHA.112.004176

20. Tso AW, Lam TK, Xu A, Yiu KH, Tse HF, Li LS, Law LS, Cheung BM, Cheung RT, Lam KS. Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology. 2011; 76:1968–75. https://doi.org/10.1212/WNL.0b013e31821e54b3

21. Holm S, Ueland T, Dahl TB, Michelsen AE, Skjelland M, Russell D, Nymo SH, Krohg-Sørensen K, Clausen OP, Atar D, Januzzi JL, Aukrust P, Jensen JK, Halvorsen B. Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PLoS One. 2011; 6:e28785. https://doi.org/10.1371/journal.pone.0028785

22. Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia. 2013; 56:10–21. https://doi.org/10.1007/s00125-012-2737-4

23. Peeters W, de Kleijn DP, Vink A, van de Weg S, Schoneveld AH, Sze SK, van der Spek PJ, de Vries JP, Moll FL, Pastenkamp G. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J. 2011; 32:1758–68. https://doi.org/10.1093/eurheartj/ehq387

24. Tu WJ, Zeng XW, Deng A, Zhao SJ, Luo DZ, Ma GZ, Wang H, Liu Q. Circulating FABP4 (fatty acid–binding protein 4) is a novel prognostic biomarker in patients with acute ischemic stroke. Stroke. 2017; 48:1531–38. https://doi.org/10.1161/STROKEAHA.117.017128

25. Li S, Bi P, Zhao W, Lian Y, Zhu H, Xu D, Ding J, Wang Q, Yin C. Prognostic utility of fatty acid-binding protein 4 in patients with type 2 diabetes and acute ischemic stroke. Neurotox. 2018; 33:309–15. https://doi.org/10.1007/s11240-017-9792-z

26. Chang L, Zhang J, Liu L, Huang Z, Han Y, Zhu Y. Fatty acid binding protein 4 is associated with stroke risk and severity in patients with acute ischemic stroke. J Neuroimmunol. 2017; 311:29–34. https://doi.org/10.1016/j.jneuroim.2017.07.011

27. Ding M, Shi JY, Xing YZ, Sun B, Fang QH, Zhang JY, Zhang QM, Chen LM, Yu DM, Li CJ. Serum adipocyte fatty acid-binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus. J Diabetes. 2018; 10:478–86. https://doi.org/10.1111/1753-0407.12549

28. Takagi W, Miyoshi T, Doi M, Okawa K, Nosaka K, Nishibe T, Matsuo N, Hirohata S, Ito H. Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention. BMC Cardiovasc. Disord. 2017; 17:258. https://doi.org/10.1186/s12872-017-0691-2

29. Chen MC, Hsu BG, Lee CJ, Yang CF, Wang JH. High serum adipocyte fatty acid binding protein level as a potential biomarker of aortic arterial stiffness in hypertensive patients with metabolic syndrome. Clin Chim Acta. 2017; 473:166–72. https://doi.org/10.1016/j.cca.2017.08.030

30. Huang H, Zheng T, Wang S, Wei L, Wang Q, Sun Z. Serum 25-hydroxyvitamin D predicts early recurrent stroke in ischemic stroke patients. Nutr Metab Cardiovasc Dis. 2016; 26:908–14. https://doi.org/10.1016/j.numecd.2016.06.009

31. Cabral NL, Muller M, Franco SC, Longo A, Moro C, Nagel V, Liberato RB, Garcia AC, Venancio VG, Gonçalves AR. Three-year survival and recurrence after first-ever stroke: the Joinville stroke registry. BMC Neurol. 2015; 15:70. https://doi.org/10.1186/s12883-015-0317-1

32. Arsava EM, Kim GM, Oliveira-Filho J, Gungor L, Noh HJ, Lordelo MJ, Avery R, Maier IL, Ay H. Prediction of
early recurrence after acute ischemic stroke. JAMA Neurol. 2016; 73:396–401. https://doi.org/10.1001/jamaneurol.2015.4949

33. Tsivgoulis G, Katsonis AH, Patousi A, Pikilidou M, Birbilis T, Mantatzis M, Yavropoulou M, Zompola C, Triantafyllou S, Papanas N, Skendros P, Terzoudi A, Georgiadis GS, et al. Stroke recurrence and mortality in northeastern Greece: the EROS Stroke Registry. J Neurol. 2018; 265:2379–87. https://doi.org/10.1007/s00415-018-9005-6

34. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8:355–69. https://doi.org/10.1016/S1474-4422(09)70025-0

35. Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, Ishimura S, Watanabe Y, Hoshina K, Tanaka M, Ohno K, Akasaka H, Ohnishi H, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol. 2014; 13:126. https://doi.org/10.1186/s12933-014-0126-7

36. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism. 2007; 56:1735–41. https://doi.org/10.1016/j.metabol.2007.07.019

37. Morigny P, Houssier M, Mousiel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016; 125:259–66. https://doi.org/10.1016/j.biochi.2015.10.024

38. Mita T, Furuhashi M, Hiramitsu S, Ishii J, Hoshina K, Ishimura S, Fuseya T, Watanabe Y, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, et al. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring). 2015; 23:359–67. https://doi.org/10.1002/oby.20954

39. Choi JY, Kim JS, Kim JH, Oh K, Koh SB, Seo WK. High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients. Neurology. 2014; 82:1142–48. https://doi.org/10.1212/WNL.0000000000002624

40. Rodriguez-Calvo R, Girona J, Alegret JM, Bosquet A, Ibarretxe D, Masana L. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol. 2017; 233:R173–84. https://doi.org/10.1530/JEO-17-0031

41. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Ninomiya Y. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010; 211:164–69. https://doi.org/10.1016/j.atherosclerosis.2010.01.032

42. Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, Fuseya T, Yamashita T, Tanaka M, Yoshida H, Shimamoto K, Miura T. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens. 2012; 25:1124–30. https://doi.org/10.1038/ajh.2012.88

43. Li B, Yang H, Zhang W, Shi Y, Qin S, Wei Y, He Y, Yang W, Jiang S, Jin H. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. PLoS One. 2018; 13:e0192347. https://doi.org/10.1371/journal.pone.0192347

44. Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, West MM, Watkins SM, Linton MF, Hotamisligil GS. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009; 15:1383–91. https://doi.org/10.1038/nm.2067

45. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, Ding K, Wang Y, Vanhoutte PM, Xu A. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010; 285:10273–80. https://doi.org/10.1074/jbc.M109.097907

46. Furuhashi M, Fucho R, Görgün C, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macroage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008; 118:2640–50. https://doi.org/10.1172/JCI34750

47. Ge XN, Bastan I, Dileepan M, Greenberg Y, Ha SG, Steen KA, Bernlohr DA, Rao SP, Sriramaraop. FABP4 regulates eosinophil recruitment and activation in allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2018; 315:L227–40. https://doi.org/10.1152/ajplung.00429.2017

48. Gong Y, Yu Z, Gao Y, Deng L, Wang M, Chen Y, Li J, Cheng B. FABP4 inhibitors suppress inflammation and oxidative stress in murine and cell models of acute lung injury. Biochem Biophys Res Commun. 2018; 496:1115–21. https://doi.org/10.1016/j.bbrc.2018.01.150

49. Wang G, Li C, Liu Y, Xia L. Macrophage Migration Inhibitory Factor Levels Correlate with Stroke Recurrence in Patients with Ischemic Stroke. Neurotox Res. 2018.
50. Hong XW, Wu DM, Lu J, Zheng YL, Tu WJ, Yan J. Lipoprotein (a) as a Predictor of Early Stroke Recurrence in Acute Ischemic Stroke. Mol Neurobiol. 2018; 55:718–26. https://doi.org/10.1007/s12035-016-0346-9

51. Obokata M, Iso T, Ohyama Y, Sunaga H, Kawaguchi T, Matsui H, Iizuka T, Fukuda N, Takamatsu H, Koitabashi N, Funada R, Takama N, Kasama S, et al. Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2018; 7:561–69. https://doi.org/10.1177/2048872616683635

52. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976; 54:541–53.

53. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20:864–70. https://doi.org/10.1161/01.STR.20.7.864

54. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35–41. https://doi.org/10.1161/01.STR.24.1.35

55. Tu WJ, Zhao SJ, Xu DJ, Chen H. Serum 25-hydroxyvitamin D predicts the short-term outcomes of Chinese patients with acute ischaemic stroke. Clin Sci (Lond). 2014; 126:339–46. https://doi.org/10.1042/CS20130284

56. Zhang Q, Ding H, Yan J, Wang W, Ma A, Zhu Z, Cianflone K, Hu FB, Hui R, Wang DW. Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: a multicenter case-control study in China. Ann Neurol. 2011; 70:265–73. https://doi.org/10.1002/ana.22404

57. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009; 66:799–808. https://doi.org/10.1002/ana.21783